Journal of Cancer Research and Therapeutics

ORIGINAL ARTICLE
Year
: 2018  |  Volume : 14  |  Issue : 9  |  Page : 282--287

Myeloperoxidase -463 G/A polymorphism is associated with lung cancer risk: A meta-analysis with 7420 cases and 9132 controls


Shengqiang Zou1, Xin Pan2, Changsong Hua4, Min Wu4, Bin He4, Zhigang Chen4 
1 The Third People's Hospital of Zhenjiang Affiliated to Jiangsu University; School of Medicine, Jiangsu University, Zhenjiang, Jiangsu, China
2 School of Medicine, Jiangsu University; Department of Medical Section, Zhenjiang Emergency Medical Center, Zhenjiang, Jiangsu, China

Correspondence Address:
Xin Pan
No. 1-19 Dingmaoqiao Road, Zhenjiang, Jiangsu
China

Aims: Several studies evaluated the association between myeloperoxidase (MPO) -463 G/A polymorphism and the risk of lung cancer. However, the results were not stable. Materials and Methods: Online electronic databases (PubMed, EMBASE, and Wanfang database) were searched. The strength of association between the MPO -463 G/A polymorphism and lung cancer risk was assessed by calculating odds ratios (OR) with 95% confidence interval (CI). Results: A total of 22 studies with 7420 cases and 9132 controls on the association between MPO -463 G/A polymorphism and lung cancer risk were included for this meta-analysis. MPO -463 G/A polymorphism was associated with a significantly decreased risk of lung cancer (OR = 0.91; 95% CI: 0.85–0.98; I 2 = 25%). In the race subgroup analysis, Asians with MPO -463 G/A polymorphism had decreased lung cancer risk (OR = 0.81; 95% CI: 0.70–0.93; I 2 = 0%). However, Caucasians did not show significant result (OR = 0.93; 95% CI: 0.86–1.02; I 2 = 36%). In the subgroup analysis according to source of control, both population-based studies and hospital-based studies were marginally significantly associated with decreased risk of lung cancer (OR = 0.90; 95% CI: 0.82–1.00; I 2 = 41% and OR = 0.91; 95% CI: 0.82–1.01; I 2 = 0%). Conclusion: The present meta-analysis suggested that the MPO -463 G/A polymorphism carriers had a protective role in lung cancer.


How to cite this article:
Zou S, Pan X, Hua C, Wu M, He B, Chen Z. Myeloperoxidase -463 G/A polymorphism is associated with lung cancer risk: A meta-analysis with 7420 cases and 9132 controls.J Can Res Ther 2018;14:282-287


How to cite this URL:
Zou S, Pan X, Hua C, Wu M, He B, Chen Z. Myeloperoxidase -463 G/A polymorphism is associated with lung cancer risk: A meta-analysis with 7420 cases and 9132 controls. J Can Res Ther [serial online] 2018 [cited 2019 Mar 22 ];14:282-287
Available from: http://www.cancerjournal.net/article.asp?issn=0973-1482;year=2018;volume=14;issue=9;spage=282;epage=287;aulast=Zou;type=0